RE: RE: News is Out Boys!Look who's calling PRX's negociator (sic) a mentally challenged monkey. (Shame on me...I couldn't resist.)
I'm waiting on the sidelines and if my big ship [NVLT] comes in, there's a good chance I'll buy back into PRX. So I'll be happy if PRX's share price goes down from here. Until the 6-month results come out in April, I consider it very unlikely for PRX's SP to go up.
The fly in the ointment is NYMX's BPH drug, which is recruiting for stage III clinical trials. NYMX's BPH drug appears to be a clone of PRX's: both are administered by injection into the prostate and they seem to have very similar effects. This much similarity has a foul smell. I've contacted IR at both biotech companies, but have received no explanation, which in itself stinks.
But there is no reason to believe that both biotechs are lying about such similar drugs. Ergo, one or both companies have a drug in clinical trials that portends to revolutionise BPH treatment. If anyone reading this happens to be a mentally-challenged monkey, that means it's so big, it's bigger than huge.